Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis

Published:2021-03 Issue:3 Volume:10 Page:2805-2814
ISSN:2224-5820
Container-title:Annals of Palliative Medicine
language:
Short-container-title:Ann Palliat Med

Author:

Liu Zheran,Chen Ye,Wei Zhigong,He Yan,Wang Jingjing,Mu Xiaoli,He Ling,Li Ruidan,Hu Xiaolin,Peng Xingchen

Publisher

AME Publishing Company

Subject

Anesthesiology and Pain Medicine,Advanced and Specialized Nursing

Link

https://apm.amegroups.com/article/download/62438/pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis;Health Technology Assessment;2024-08

2. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-09-07

3. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?;Pharmacology & Therapeutics;2023-09

4. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP